Accuryn vs Veeva Systems
Side-by-side comparison of AI visibility scores, market position, and capabilities
Accuryn is the hemodynamic monitoring system developed by Retia Medical, providing continuous cardiac output and fluid responsiveness measurement in critical care via a proprietary non-invasive algorithm; received FDA 510(k) clearance;
About
Accuryn is a critical care hemodynamic monitoring system developed by Retia Medical, a medical device company headquartered in Ann Arbor, Michigan. The Accuryn Monitoring System provides continuous, real-time measurement of cardiac output, stroke volume, and fluid responsiveness in critically ill patients — parameters that are essential for guiding hemodynamic management in the intensive care unit (ICU) but historically required invasive pulmonary artery catheter (PAC) placement to measure. Retia Medical's proprietary pulse contour analysis algorithm enables continuous cardiac output monitoring using standard arterial line waveforms already present in most ICU patients, without requiring additional invasive access.
Veeva Systems (VEEV) reported $2.7B revenue in FY2025, up 14% YoY. #1 cloud platform for life sciences. ~8,000 employees. HQ: Pleasanton, CA. Market cap ~$40B.
About
Veeva Systems Inc. is the leading cloud software provider for the global life sciences industry, headquartered in Pleasanton, California. Founded in 2007 by Peter Gassner (a former Salesforce executive) and Matt Wallach, Veeva built its platform on Salesforce and later developed its own Vault cloud infrastructure. The company became a public benefit corporation (PBC) in 2021. Veeva reported revenues of $2.7B in fiscal year 2025 (ending January 2025), up 14% year-over-year, with a market capitalization of approximately $40B.
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.